









Markets
/
Stocks
/
nasdaq-flgt
/

Fulgent Genetics Inc

FLGT

26.360USD

+4.050+18.15%

Close 11/07, 16:00（ET）Quotes delayed by 15 min

813.31MMarket Cap

LossP/E TTM



Fulgent Genetics Inc

26.360

+4.050+18.15%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Fulgent Genetics Inc

Currency: USD Updated: 2025-11-07

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Fulgent Genetics Inc's Score

Industry at a Glance

Industry Ranking

24 / 78

Overall Ranking

129 / 4614

Industry

Healthcare Providers & Services

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Buy

Current Rating

25.333

Target Price

-3.89%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Fulgent Genetics Inc Highlights

StrengthsRisks

Fulgent Genetics, Inc. is a technology-based genetic company with a laboratory services business and a therapeutic development business. The Company’s laboratory services business includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile (PK) profile of new and existing cancer drugs. Its technology platform for its laboratory services business includes gene probes, data suppression and comparison algorithms, learning software, and laboratory information management systems. The platform provides a test menu, the ability to rapidly develop and launch new tests and customizable test offerings. The Company also offers next-generation sequencing (NGS) services.

Undervalued

The company’s latest PE is -15.83, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 16.62M shares, decreasing 9.35% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 1.73K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-07

The company's current financial score is 6.92, which is lower than the Healthcare Providers & Services industry's average of 7.24. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 81.80M, representing a year-over-year increase of 15.17%, while its net profit experienced a year-over-year increase of 117.65%.

Score

Industry at a Glance

Previous score

6.92

Change



Financials

8.59

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.80

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.49

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.60

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Fulgent Genetics Inc's Company Valuation

Currency: USD Updated: 2025-11-07

The company’s current valuation score is 8.79, which is higher than the Healthcare Providers & Services industry's average of 7.09. Its current P/E ratio is -15.83, which is -148.09% below the recent high of 7.61 and -203.36% above the recent low of -48.02.

Score

Industry at a Glance

Previous score

8.79

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 24/78

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-07

The company’s current earnings forecast score is 7.33, which is lower than the Healthcare Providers & Services industry's average of 7.56. The average price target for Fulgent Genetics Inc is 25.00, with a high of 30.00 and a low of 21.00.

Score

Industry at a Glance

Previous score

7.33

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Buy

Current Rating

25.333

Target Price

-3.89%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Fulgent Genetics Inc

FLGT

CVS Health Corp

CVS

HCA Healthcare Inc

HCA

Teladoc Health Inc

TDOC

Tenet Healthcare Corp

THC

Universal Health Services Inc

UHS

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-07

The company’s current price momentum score is 8.79, which is higher than the Healthcare Providers & Services industry's average of 7.06. Sideways: Currently, the stock price is trading between the resistance level at 28.46 and the support level at 23.16, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.89

Change

2.9

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.232

Buy

RSI(14)

72.220

Buy

STOCH(KDJ)(9,3,3)

54.287

Buy

ATR(14)

1.012

High Vlolatility

CCI(14)

272.171

Overbought

Williams %R

18.868

Overbought

TRIX(12,20)

0.093

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

23.488

Buy

MA10

23.194

Buy

MA20

23.186

Buy

MA50

22.682

Buy

MA100

21.220

Buy

MA200

19.724

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-07

The company’s current institutional recognition score is 5.00, which is lower than the Healthcare Providers & Services industry's average of 6.96. The latest institutional shareholding proportion is 54.30%, representing a quarter-over-quarter decrease of 39.01%. The largest institutional shareholder is The Vanguard, holding a total of 1.16M shares, representing 3.79% of shares outstanding, with 16.44% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Hsieh (Ming)

8.76M

-0.07%

BlackRock Institutional Trust Company, N.A.

1.62M

-4.09%

Millennium Management LLC

1.44M

The Vanguard Group, Inc.

Star Investors

1.16M

-0.37%

Dimensional Fund Advisors, L.P.

1.13M

+10.25%

Acadian Asset Management LLC

1.12M

+38.71%

Gao (Hanlin)

873.75K

-0.12%

Citadel Advisors LLC

603.65K

+38.53%

Point72 Asset Management, L.P.

Star Investors

544.88K

+1405.81%

State Street Investment Management (US)

513.80K

+1.38%

Risk Assessment

Currency: USD Updated: 2025-11-07

The company’s current risk assessment score is 7.54, which is higher than the Healthcare Providers & Services industry's average of 5.45. The company's beta value is 0.68. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.